Here’s the short version: there’s now an oral Wegovy, a once-daily semaglutide pill approved in December 2025 that matched the injection for weight loss in trials, so if needles were your holdup, that barrier’s gone. Retatrutide, the triple-receptor drug getting the loudest headlines, is still investigational and not something you can fill at the pharmacy today. Let me walk you through both, because one’s here and one’s coming.
It’s been a fast year in metabolic medicine. If you live with obesity or type 2 diabetes, these two developments are worth understanding.
Key Takeaways
- Oral Wegovy (a once-daily semaglutide pill) was approved in December 2025 and produced about 16.6% weight loss at the 25 mg dose in the OASIS-4 trial, similar to the injection.
- Oral Ozempic is now a thing! It’s identical to the oral Wegovy just approved for diabetes. Same molecule, different brands.
- Retatrutide (Eli Lilly) hits three receptors at once, GIP, GLP-1, and glucagon, and produced up to 28.3% weight loss at 80 weeks in trials.
- Retatrutide is still investigational, not FDA approved, and not fillable yet. The timeline is uncertain.
- No matter how strong the drug, fast weight loss can strip muscle along with fat, so a prescription is only part of the plan.
Is there really a Wegovy pill now?
Most people know semaglutide by two names: Ozempic for diabetes and Wegovy for weight loss. Both have been injections. As of December 2025, there’s an oral version of Wegovy too, a once-daily pill. Recently, the oral semaglutide for diabetes, called Rybelsus, was reformulated and now is available under the brand name Ozempic.
The dosing starts at 1.5 mg and climbs to 25 mg a day. In the OASIS-4 trial, the 25 mg pill produced about 16.6% weight loss, which lands right in the range of the injection. So if needles were the reason you’d avoided this whole class of medication, that barrier is gone.
Oral Wegovy vs oral Ozempic: what’s the difference?
Let me clear up the names, because they trip everyone up.
The oral semaglutide used for type 2 diabetes used to be called Rybelsus. It’s now called Ozempic, but it’s been around a while at lower doses (up to 9mg). Semaglutide at higher doses for weight loss is the oral Wegovy (up to 25mg). It’s the same molecule, just a different brand and dose depending on what it’s treating.
What is retatrutide, and why is everyone asking about it?
The drug my patients keep bringing up is retatrutide, from Eli Lilly. What makes it different is that it works on three receptors at once: GIP, GLP-1, and glucagon. The medications you know today hit one or two. This is the first to add glucagon to the mix.
The phase 3 data is striking. In the obesity trials, people lost up to 28.3% of their body weight at 80 weeks, and about 30% at 104 weeks in those with severe obesity. That’s the range we used to see only with bariatric surgery. In the first phase 3 trial for type 2 diabetes, it lowered A1C by up to 2%, with about 16.8% weight loss at 40 weeks.
When can you actually get retatrutide?
Here’s the honest caveat: retatrutide is still investigational. It’s not FDA approved, it’s not something you can fill at the pharmacy today, and the timeline is still uncertain. Think of it as a preview of where the field is heading, not a prescription you can pick up this week.
The part nobody puts on the label: no matter how powerful these drugs get, when you lose weight fast, a real share of what comes off can be muscle instead of fat. And muscle is your largest metabolic organ. A bigger number on the scale isn’t automatically a better outcome.
Will these drugs cost you muscle?
They can, if you let the medication do all the thinking. That’s why I treat the drug as one tool, not the whole plan.
Whichever one you’re on, the work around it is what protects you: enough protein, resistance training, and keeping an eye on your body composition so you’re losing fat and holding onto muscle. A prescription isn’t a plan.
If you’re considering one of these medications, or you’re already on one and want to do it right, that’s exactly what we do. Learn about comprehensive weight management or book a visit.
I’m Dr. Lindsey VanDyke, double board-certified in endocrinology. We see patients in Mansfield, Texas and by telehealth across seven states, including California.
This article is educational and isn’t a substitute for medical advice from your own clinician. Retatrutide is investigational and not FDA approved as of this writing.
Frequently asked questions
Is there a Wegovy pill?
Yes. An oral version of Wegovy, once-daily semaglutide, was approved in December 2025. At the 25 mg dose it produced about 16.6% weight loss in the OASIS-4 trial.
Is oral Wegovy as effective as the injection?
In trials the 25 mg pill landed in a similar range to injectable semaglutide. The right choice still depends on your history, your other medications, and your preferences.
What is retatrutide?
It’s an investigational Eli Lilly drug that works on three receptors at once, GIP, GLP-1, and glucagon. In trials it produced up to 28.3% weight loss at 80 weeks.
When will retatrutide be available?
It’s not FDA approved yet and the timeline is uncertain. You can’t fill it at a pharmacy today.
Do weight-loss drugs make you lose muscle?
Fast weight loss can take muscle along with fat. That’s why protein, resistance training, and body-composition monitoring matter as much as the prescription itself.
Sources: Eli Lilly: retatrutide phase 3 obesity results (TRIUMPH-1) · Eli Lilly: retatrutide phase 3 type 2 diabetes results (TRANSCEND-T2D-1) · NEJM: oral semaglutide 25 mg (OASIS-4) · Novo Nordisk / FDA: oral Wegovy approval